IR Information
IR Information
News Release
News release
-
2025.11.01
Notice of Consulting Services Contract Conclusion with New Securities Firm
(242KB)
-
2025.10.22
Announcement of Completion of Patient Enrollment for the Phase IIa Clinical Trial of PC-SOD
(261KB)
-
2025.09.24
Our CEO (Director of the Japan Biotechnology Association) made a statement at the Central Social Insurance Medical Council
(248KB)
-
2025.09.11
Report on the Conduct of the PC-SOD Phase III Clinical Trial Investigator Meeting
(536KB)
-
2025.09.10
Request for notification of changes to shareholder register entries, such as address changes
(251KB)
Financial Information
Disclosure
Financial Results
| 23rd Fiscal Period (Results for March 2025) | |
|---|---|
| Net sales (Thousands of yen) | 61,438 |
| Operating income (thousand yen) | 1,420,545 |
| Net income (thousand yen) | 1,084,701 |
| Net assets (Thousands of yen) | 5,257,192 |
| Total assets (Thousands of yen) | 5,585,185 |
| Equity ratio (%) | 94.1 |
Business Report
Business report
23rd Term
Business Overview
(544KB)
22nd Term
Business Overview
(558KB)
21th Term
Business Overview
(485KB)
20th Term
Business Overview
(568KB)
19th Term
Business Overview
(595KB)
